Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin

October 1, 2013CirculationOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to assess the management strategies and outcomes associated with major bleeding incidents during treatment with dabigatran or warfarin.
Reviewed clinical data from multiple trials including NCT00262600, NCT00291330, NCT00680186, NCT00329238, and NCT00558259.
Examined outcomes related to major bleeding events while on anticoagulant therapy.
Analyzed various management strategies employed during these incidents.
Major bleeding occurred in a significant proportion of patients on both dabigatran and warfarin with noted differences in management outcomes.
Outcomes were more favorable in certain management pathways compared to others, indicating potential for improved protocol adherence.
Significant differences in bleeding event resolutions were observed depending on the anticoagulant used.

Answers are grounded in this paper and cite their sources.

Evaluates management and outcomes of major bleeding with dabigatran or warfarin, suggesting safety considerations.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Majeed et al. (2013) studied this question.

View Full Paper

Ask AI

Bookmark

Share